Technical parameters and documentation standards Manufactured under Current Good Manufacturing Practice regulations Adheres to documented USP criteria for laboratory-grade water Individual batches verified for endotoxin and sterility markers Certificate of Analysis available for laboratory audit trails Maintaining research compound stability and efficacy Unpunctured vials should be maintained at controlled room temperature
10.1007/s00404-014-3466-3 164
The protocol was approved by the Institutional Animal Care and Use Committee at the Academy of Military Medical Sciences (AMMS) (protocol code: IACUC-DWZX-2021-053, date of approval: 9 Sep 2021)
Sevoflurane [(F 3 C) 2 COCH 2 F] is a widely used anesthetic, which may lose HF in the anesthetic circuit to generate 2-(fluoromethoxy)-1,1,3,3,3-pentafluoro-1-propene (Compound A), which is nephrotoxic to rats (Anders, 2005)
The clinical trial protocol starts at 0.25 mg to 0.3 mg weekly and increases every 4 weeks through escalation steps of 0.6 mg, 1.2 mg, 1.8 mg, and finally 2.4 mg
